INCLINE VILLAGE, Nev.,
March 4, 2020 /PRNewswire/
-- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI)
announces that it will release its 2019 fourth quarter and full
year financial results for the period ended December 31, 2019, on Wednesday, March 11, 2020, after market close.
PDL's management will host a conference call and webcast that day
at 4:30 p.m. Eastern time to discuss
the operating and financial results and recent developments.
A slide presentation relating to the call will be available
via the webcast link on the PDL website at http://www.pdl.com/.
Conference Call Details
To access the live conference
call via phone, please dial (844) 535-4071 from the United States and Canada or (706) 679-2458 internationally. The
conference ID is 8017938. Please dial in approximately 10
minutes prior to the start of the call. A telephone replay will be
available for one week following the call and may be accessed by
dialing (855) 859-2056 from the United
States and Canada or (404)
537-3406 internationally. The replay passcode is 8017938.
To access the live and subsequently archived webcast of the
conference call, go to the Company's website and go to "Events
& Presentations." Please connect to the website at least 15
minutes prior to the call to allow for any software download that
may be necessary.
About PDL BioPharma
Throughout its history, PDL's
mission has been to improve the lives of patients by aiding in the
successful development of innovative therapeutics and healthcare
technologies. PDL BioPharma was founded in 1986 as Protein Design
Labs, Inc. when it pioneered the humanization of monoclonal
antibodies, enabling the discovery of a new generation of targeted
treatments that have had a profound impact on patients living with
different cancers as well as a variety of other debilitating
diseases. In 2006, the Company changed its name to PDL BioPharma,
Inc.
As of December 2019, PDL ceased
making additional strategic transactions and investments and is
pursuing a formal process to unlock the value of its portfolio by
monetizing its assets and ultimately distributing net proceeds to
shareholders.
For more information please visit https://www.pdl.com/.
NOTE: PDL, PDL BioPharma, the PDL logo and associated
logos and the PDL BioPharma logo are trademarks or registered
trademarks of, and are proprietary to, PDL BioPharma, Inc. which
reserves all rights therein.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-2019-fourth-quarter-and-full-year-financial-results-on-march-11-2020-301011634.html
SOURCE PDL BioPharma, Inc.